Literature DB >> 7522267

CSF concentration gradients of monoamine metabolites in patients with hydrocephalus.

J Malm1, B Kristensen, J Ekstedt, P Wester.   

Abstract

Concentration gradients of homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylglycol (MHPG), were assessed in 762 successive CSF fractions (2 ml lumbar CSF) from 15 patients with the adult hydrocephalus syndrome (AHS) and 11 patients with hydrocephalus of other causes (mixed group). A mean volume of 49.6 (SD 11.8) ml CSF was removed in the AHS group and 56.4 (10.2) ml in the mixed group. The CSF was collected with a specially designed carousel fraction collector and the corresponding CSF dynamics were continuously registered by a constant pressure CSF infusion method. Pronounced gradients in CSF HVA and CSF 5-HIAA were seen in both patient groups in the first 25 ml of CSF removed. The concentration curves levelled off, despite the removal of larger amounts of CSF and stabilised at about twice the initial concentrations. This phenomenon has not been described before. Concentrations of HVA and 5-HIAA in the first CSF fraction correlated strongly with concentrations in fractions up to about 40 ml. A positive correlation between the first fraction of CSF HVA and CSF 5-HIAA concentrations and CSF outflow conductance was found in the AHS group. There was no gradient in MHPG. It is suggested that the rostrocaudal gradients in CSF HVA and 5-HIAA may be explained by a downward flow of CSF along the spinal cord with absorption of metabolites occurring during passage. Mixing of CSF from different CSF compartments, extraventricular production sites of CSF, clearance of metabolites to venous blood or extracellular fluid, and CSF outflow conductance are probably important determinants of the plateau phase in patients with hydrocephalus. It is concluded that lumbar CSF does not exclusively reflect the concentrations of HVA, 5-HIAA, or MHPG in the ventricles. It should be noted that these results obtained in patients with hydrocephalus may not be applicable to other groups of patients or normal subjects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7522267      PMCID: PMC1073122          DOI: 10.1136/jnnp.57.9.1026

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  40 in total

1.  Gradients of biogenic amine metabolites in cerebrospinal fluid.

Authors:  L Siever; H Kraemer; R Sack; P Angwin; P Berger; V Zarcone; J Barchas; H K Brodie
Journal:  Dis Nerv Syst       Date:  1975-01

2.  5-hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases.

Authors:  G W Ashcroft; T B Crawford; D Eccleston; D F Sharman; E J MacDougall; J B Stanton; J K Binns
Journal:  Lancet       Date:  1966-11-12       Impact factor: 79.321

Review 3.  Monoamine metabolites in lumbar CSF: the question of their origin in relation to clinical studies.

Authors:  E Garelis; S N Young; S Lal; T L Sourkes
Journal:  Brain Res       Date:  1974-10-11       Impact factor: 3.252

4.  Norepinephrine metabolism in the central nervous system of man: studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid.

Authors:  T N Chase; E K Gordon; L K Ng
Journal:  J Neurochem       Date:  1973-09       Impact factor: 5.372

Review 5.  Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain.

Authors:  A T Moir; G W Ashcroft; T B Crawford; D Eccleston; H C Guldberg
Journal:  Brain       Date:  1970       Impact factor: 13.501

6.  Extraventricular origin of the cerebrospinal fluid: formation rate quantitatively measured in the spinal subarachnoid space of dogs.

Authors:  O Sato; T Asai; Y Amano; M Hara; R Tsugane; M Yagi
Journal:  J Neurosurg       Date:  1972-03       Impact factor: 5.115

7.  5-hydroxyindoleacetic acid in cerebrospinal fluid of hydrocephalic children.

Authors:  H Andersson; B E Roos
Journal:  Acta Paediatr Scand       Date:  1969-11

8.  Effect of tryptophan administration on 5HIAA in cerebrospinal fluid in man.

Authors:  D Eccleston; G W Ashcroft; T B Crawford
Journal:  J Neurol Neurosurg Psychiatry       Date:  1970-04       Impact factor: 10.154

9.  The active transport of 5-hydroxyindol-3-ylacetic acid and 3-methoxy-4-hydroxyphenylacetic acid from a recirculatory perfusion system of the cerebral ventricles of the unanaesthetized dog.

Authors:  G W Ashcroft; R C Dow; A T Moir
Journal:  J Physiol       Date:  1968-12       Impact factor: 5.182

10.  Use of cerebrospinal fluid drawn at pneumoencephalography in the study of monoamine metabolism in man.

Authors:  E Garelis; T L Sourkes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-06       Impact factor: 10.154

View more
  4 in total

1.  Genome-wide association study of monoamine metabolite levels in human cerebrospinal fluid.

Authors:  J J Luykx; S C Bakker; E Lentjes; M Neeleman; E Strengman; L Mentink; J DeYoung; S de Jong; J H Sul; E Eskin; K van Eijk; J van Setten; J E Buizer-Voskamp; R M Cantor; A Lu; M van Amerongen; E P A van Dongen; P Keijzers; T Kappen; P Borgdorff; P Bruins; E M Derks; R S Kahn; R A Ophoff
Journal:  Mol Psychiatry       Date:  2013-01-15       Impact factor: 15.992

2.  Monoamine neurotransmitters and their metabolites in the mature rabbit brain following induction of hydrocephalus.

Authors:  M R Del Bigio; J E Bruni; J P Vriend
Journal:  Neurochem Res       Date:  1998-11       Impact factor: 3.996

3.  Influence of comorbidities in idiopathic normal pressure hydrocephalus - research and clinical care. A report of the ISHCSF task force on comorbidities in INPH.

Authors:  Jan Malm; Neill R Graff-Radford; Masatsune Ishikawa; Bo Kristensen; Ville Leinonen; Etsuro Mori; Brian K Owler; Mats Tullberg; Michael A Williams; Norman R Relkin
Journal:  Fluids Barriers CNS       Date:  2013-06-10

Review 4.  Nonsurgical therapy for hydrocephalus: a comprehensive and critical review.

Authors:  Marc R Del Bigio; Domenico L Di Curzio
Journal:  Fluids Barriers CNS       Date:  2016-02-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.